ALDER BIOPHARMACEUTICALS INC Form SC 13G February 02, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.)*

Alder BioPharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of class of securities)


014339105

(CUSIP number)

December 31, 2014

(Date of event which requires filing of this statement)

Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form SC 13G



- " Rule 13d-1(b)
- "Rule 13d-1(c)
- x Rule 13d-1(d)
- * The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CU	SIP No.	01	4339105 SCH	HEDULE 13G	Page 2 of 6 Pages
1.	Name	of R	eporting Person:		
2.	Novo . Check	the	Appropriate Box if a Member of Group b) "	(See Instructions):	
3.	SEC U				
4.	Citizeı	nshij	or Place of Organization:		
	Denma		Sole Voting Power:		
Nun	nber of				
	ares		3,201,183 Shared Voting Power:		
Bene	ficially				
	ned By	7.	0 Sole Dispositive Power:		
Rep	orting				
	rson	8.	3,201,183 Shared Dispositive Power:		
W	ith:				
9.	Aggre	gate	0 Amount Beneficially Owned by Each R	eporting Person:	
10.	3,201, Check		ne Aggregate Amount in Row (9) Exclud	les Certain Shares: "	

11. Percent of Class Represented By Amount In Row (9):

Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form SC 13G

	8.7% (1)
12.	Type of Reporting Person:

CO

(1) Based upon 36,946,247 shares of the Issuer s Common Stock outstanding, comprised of 30,946,247 shares of Common Stock outstanding as of November 30, 2014 and an additional 6,000,000 shares of Common Stock to be outstanding pursuant to the Issuer s registered offering, as reported in the Issuer s Form 424B4 (Prospectus) filed with the Securities and Exchange Commission on January 8, 2015.

CUSIP No. **014339105**

SCHEDULE 13G

Page 3 of 6 Pages

Item 1. (a) Name of Issuer:

Alder BioPharmaceuticals, Inc.

(b) Address of Issuer s Principal Executive Offices:

11804 North Creek Parkway South Bothell, WA 98011

Item 2. (a) Name of Person Filing:

Novo A/S, a Danish public limited company wholly owned by Novo Nordisk Fonden (the <u>Foundation</u>), a Danish commercial foundation. Novo A/S is the holding company in the group of Novo companies (currently comprised of Novo Nordisk A/S, Novozymes A/S and New Xellia Group A/S) and is responsible for managing the Foundation s assets, including its financial assets. Based on the governance structure of Novo A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo A/S.

(b) Address or Principal Business Office or, if none, Residence:

Tuborg Havnevej 19

2900 Hellerup, Denmark

(c) Citizenship or Place of Organization:

Novo A/S: Denmark

(d) Title of Class of Securities:

Common Stock

(e) CUSIP Number:

014339105

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

CUSIP No. 014339105

SCHEDULE 13G

Page 4 of 6 Pages

Item 4. Ownership:

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:	3,201,183	(1)		
(b) Percent of class:	8.7%	(2)		
(c) Number of shares as to which such person has:				
(i) Sole power to vote or to direct the vote:	3,201,183	(1)		
(ii) Shared power to vote or to direct the vote:				
(iii) Sole power to dispose or to direct the disposition of:	3,201,183	(1)		
(iv) Shared power to dispose or to direct the disposition of:				

- (1) The board of directors of Novo A/S (the <u>Novo Board</u>), currently comprised of Sten Scheibye, Goran Ando, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has investment and voting control over the securities of the Issuer held by Novo A/S (the <u>Novo Shares</u>) and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Novo Shares. Peter Bisgaard, a member of the board of directors of the Issuer, is employed as a Partner at Novo Ventures (US) Inc., which provides certain consultancy services to Novo A/S. Mr. Bisgaard is not deemed a beneficial owner of, and does not have a reportable pecuniary interest in, the Novo Shares.
- (2) Based upon 36,946,247 shares of the Issuer s Common Stock outstanding, comprised of 30,946,247 shares of Common Stock outstanding as of November 30, 2014 and an additional 6,000,000 shares of Common Stock to be outstanding pursuant to the Issuer s registered offering, as reported in the Issuer s Form 424B4 (Prospectus) filed with the Securities and Exchange Commission on January 8, 2015.

Item 5. Ownership of Five Percent or Less of a Class:

Not applicable.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person:

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

Not applicable.

Item 8. Identification and Classification of Members of the Group:

Not applicable.

CUSIP No. **014339105** SCHEDULE 13G Page 5 of 6 Pages

Item 9. Notice of Dissolution of Group:

Not applicable.

Item 10. Certifications:

Not applicable.

CUSIP No. 014339105

SCHEDULE 13G

Page 6 of 6 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 2, 2015

Novo A/S

/s/ Thorkil Kastberg Christensen

By: Thorkil Kastberg Christensen

Its: Chief Financial Officer